Related Experiment Videos
Transforming growth factor-beta: possible roles in carcinogenesis
A B Roberts1, N L Thompson, U Heine
1Laboratory of Chemoprevention, National Cancer Institute, Bethesda, MD 20892.
British Journal of Cancer
|June 1, 1988
Summary
Transforming growth factor-beta (TGF-beta) aids wound healing and tissue remodeling. However, tumor cells may exploit TGF-beta to promote cancer growth by influencing the tumor microenvironment and evading its inhibitory effects.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Transforming growth factor-beta (TGF-beta) is a key regulatory protein involved in cellular processes.
- Primary sources like platelets and bone suggest TGF-beta's role in healing and remodeling.
- In vitro studies show TGF-beta attracts monocytes and fibroblasts, promoting extracellular matrix accumulation.
Purpose of the Study:
- To explore the proposed role of TGF-beta in tumor growth.
- To investigate how TGF-beta secreted by tumor cells may influence the tumor microenvironment.
- To understand the mechanisms by which tumor cells evade TGF-beta's growth inhibitory effects.
Main Methods:
- Literature review and synthesis of existing in vitro and in vivo data on TGF-beta.
- Comparative analysis of TGF-beta's functions in wound healing, embryogenesis, and cancer.
- Examination of cellular mechanisms for TGF-beta evasion by tumor cells.
Main Results:
- TGF-beta is implicated in stimulating granulation tissue formation and has specific expression patterns during embryogenesis.
- Tumor-secreted TGF-beta may indirectly promote tumor growth by suppressing immune responses and enhancing angiogenesis and connective tissue formation.
- Tumor cells frequently escape direct TGF-beta growth inhibition through various molecular mechanisms.
Conclusions:
- TGF-beta plays a dual role, promoting healing but potentially aiding tumor progression.
- Tumor cells have evolved strategies to bypass TGF-beta's antiproliferative actions.
- Understanding these mechanisms is crucial for developing targeted cancer therapies.